Prashant Kohli, Chief Executive Officer at Grace Therapeutics, Inc. (GRCE), bought 100,000 shares at $2.14 ($214K) on 2026-09-09, disclosed to the SEC on 2026-09-10.
CEO Prashant Kohli purchased 100,000 shares for $214,000 at $2.14, marking the largest insider purchase in the company's history. This significant capital commitment by the CEO suggests strong conviction in the stock's potential recovery.
The stock is trading near its 52-week low of $1.85, down 17.51% from the high of $2.57, and has underperformed over the last 30 days with a 1.85% decline.
Insiders were net buyers of Grace Therapeutics stock during the past year; track that momentum.
The stock is trading at a forward P/E of -4.62, indicating the market expects continued losses, and short interest represents 8.68% of the float.
Something here stands out, but not much.